Moderate Evidence
Research Overview
Sulanemadlin Research for Retinoblastoma
An evidence-based overview of research examining Sulanemadlin in the context of retinoblastoma. This page synthesizes findings from peer-reviewed literature.
Research Summary
Advancium Biosciences partnership (2023) developing sulanemadlin for retinoblastoma via intravitreal delivery. Retinoblastoma is a TP53wt tumor type well-suited to dual MDM2/MDMX inhibition mechanism. Pediatric formulation under development.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.